Quick Takeaways
- Fred E. Cohen has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $15,056,328.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Fred E. Cohen
- Location
- Fort Worth, TX
- Summary
- The estimated net worth of Fred E. Cohen is at least $15,056,328 dollars as of 07 Jan 2026. Fred E. Cohen is the Director, 10%+ Owner of Kyverna Therapeutics, Inc. and owns shares of Kyverna Therapeutics, Inc. (KYTX) stock worth about $9.58M. Fred E. Cohen is the Director of CareDx, Inc. and owns shares of CareDx, Inc. (CDNA) stock worth about $2.81M. Fred E. Cohen is the Director of Intellia Therapeutics, Inc. and owns shares of Intellia Therapeutics, Inc. (NTLA) stock worth about $1.94M. Fred E. Cohen is the Director of Progyny, Inc. and owns shares of Progyny, Inc. (PGNY) stock worth about $725K.
- Signature
- /s/ James Basta, attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Fred E. Cohen and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Kyverna Therapeutics, Inc. ($9,580,576).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Fred E. Cohen
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| KYTX | Kyverna Therapeutics, Inc. | Director, 10%+ Owner | $9,580,576 | 29 May 2025 | ||
| CDNA | CareDx, Inc. | Director | $2,811,026 | 13 Jun 2025 | ||
| NTLA | Intellia Therapeutics, Inc. | Director | $1,939,685 | +$1,402,500 | +261% | 05 Jan 2026 |
| PGNY | Progyny, Inc. | Director | $725,041 | 23 May 2024 | ||
| URGN | UroGen Pharma Ltd. | Director | 06 Aug 2024 |
Insider Transactions Reported by Fred E. Cohen:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.